Koos de Wit
@dewitkoos.bsky.social
MD | PhD | Resident at the Department of Gastroenterology and Hepatology
@amsterdamumc and @spaarnegasthuis
@amsterdamumc and @spaarnegasthuis
Reposted by Koos de Wit
Most viewed in the last 7 days from JAMA: The addition of simvastatin plus rifaximin to standard therapy does not improve outcomes in patients with decompensated liver cirrhosis.
https://ja.ma/3EE33uQ
https://ja.ma/3EE33uQ
February 18, 2025 at 8:03 PM
Most viewed in the last 7 days from JAMA: The addition of simvastatin plus rifaximin to standard therapy does not improve outcomes in patients with decompensated liver cirrhosis.
https://ja.ma/3EE33uQ
https://ja.ma/3EE33uQ
Just published in @jama.com: Simvastatin and Rifaximin in Decompensated Cirrhosis. @salvatore-piano.bsky.social @juanabraldes.bsky.social @easlnews.bsky.social @bavenocoop.bsky.social #liversky jamanetwork.com/journals/jam...
February 6, 2025 at 10:06 AM
Just published in @jama.com: Simvastatin and Rifaximin in Decompensated Cirrhosis. @salvatore-piano.bsky.social @juanabraldes.bsky.social @easlnews.bsky.social @bavenocoop.bsky.social #liversky jamanetwork.com/journals/jam...